3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Lymphoma, Follicular
5
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Advanced Solid Tumors
1
Interventions
Gemcitabine
2
10-propargyl-10-deazaaminopterin
2
tislelizumab
1
ontuxizumab
1
glofitamab
1
enasidenib
1
duvelisib
1
brincidofovir
1
belinostat
1
WW Domain-Containing Oxidoreductase
1
Vitamin B 12
1
Sensitivity and Specificity
1
MLN 8237
1
MAC-ST-001
1
Folic Acid
1
Fentanyl
1
Fenretinide
1
Commerce
1
Bendamustine Hydrochloride
1
(N(1),N(12))bis(ethyl)-6,7-dehydrospermine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Immunoblastic Lymphadenopathy
×
duvelisib
×
Clear all
NCT06522737
2026-04-06
TERZO
SecuraBio
Phase 3
Recruiting
124 enrolled